Summary:
Pathologic analysis of tumor tissue biopsies is the gold standard
for the initial diagnosis of cancer. However, recently liquid
biopsies, which analyze tumor-derived material circulating in the
bloodstream and other bodily fluids, are rapidly gaining traction in
the clinic. These tests offer considerable potential in oncology,
which include early detection, monitoring treatment response and
disease recurrence. Liquid biopsy biomarkers include circulating
tumor cells, cell-free DNA, nanoparticles, and extracellular
vesicles (EVs).